Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome

• Conditions: Coronary Heart Disease

• Registration Number: NCT02967718
• Lead Sponsor: Jingqing Hu

Brief Summary

Coronary heart disease is still the major cause of death in China. Chinese medicine plays more and more important role in CHD prevention and treatment. Phlegm and blood stasis are its major pathological basis. Based on that, the investigator aims to evaluate the evolutionary process of CHD phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method so as to guide the clinical treatment of CHD.

Detailed Description

Coronary heart disease (CHD) is a major cause of myocardial infarct (MI) and death induced by atherosclerosis or coronary artery spasm. Despite improvements in interventional and pharmacological therapy for acute MI, the mortality early after AMI remains high. Nowadays, as our life quality develops and dietary structure changes, the morbidity of hyperlipidemia dramatically increased. Based on the Chinese medicine, hyperlipidemia belongs to phlegm and it's the basis of atherosclerosis, blood-stasis is the pathological basis of ischemia. Therefore, the investigator proposes that phlegm and blood-stasis syndrome is the main differentiation on CHD. Based on that, the investigator prospectively and retrospectively explores the evolutionary process of CHD phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method.It will provide evidence and guidance to the future clinical treatment using Chinese medicine.

Study Timeline

• Study Start: 2016-09
• Status Verified: 2016-11
• Study First Submitted: 2016-11-16
• Study First Submitted QC: 2016-11-16
• Study First Posted: 2016-11-18
• Last Update Submitted: 2016-11-20
• Last Update Posted: 2016-11-22
• Primary Completion: 2017-03
• Study Completion: 2017-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 13000

Inclusion Criteria

• Healthy or metabolism syndrome people
• Clinical diagnosis of CHD stable stage or acute coronary disease or CHD heart failure

Exclusion Criteria

• Any inflammation, fever, trauma, burn or operation within 1 week
• Obstructive pulmonary disease
• Cerebral vascular disease
• Severe renal or hepatic dysfunction
• Malignant neoplasms
• Hematopoietic system disease
• Sever mental disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
all cause mortality	6 months

Trial Locations

Locations (1)

The First Integrative Hospital of Beijing; 🇨🇳 Beijin, Beijing, China